Jaenisch, Muraru, and Pandey discuss how regulators will audit pharma against its own AI policies and ways QA and regulatory teams can build defensible, inspection-ready AI practices.
|Articles|December 7, 2011
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-12-07-2011
- Volume 7
- Issue 12
Technical Perspectives: Antibody Drug Conjugates
Author(s)Patricia Van Arnum
A podcast moderated by Patricia Van Arnum, executive editor of Pharmaceutical Technology.
Advertisement
Antibody drug conjugates represent a niche area of drug development. Antibody drug conjugates combine a small-molecule, often a cytotoxic compound, to a monoclonal antibody. Grant E. Boldt, PhD, director of European business development for SAFC, discusses manufacturing considerations in producing antibody drug conjugates with Patricia Van Arnum, executive editor of Pharmaceutical Technology. Listen to the
Articles in this issue
almost 15 years ago
World Health Organization Issues Progress Report on Combating HIV/AIDSalmost 15 years ago
CSR and Sustainability in the Newsalmost 15 years ago
Pharmaceutical Companies Target Green Manufacturingalmost 15 years ago
Biosimilars' Technology NeedsAdvertisement
Related to this article
Impurity deficiencies in submissions are remarkably consistent. Subathra Ramamoorthy, Veranova, explains how to catch them before agency filing.
USP’s Sheehan and Liu talk at AAPS PharmSci 360 abou getting novel excipients past the monograph hurdle through early engagement with FDA.
CDMOs announced expansions, exhibitors showcased automated equipment, and supply chain strategy discussions were a focus at CPHI Milan 2026.
Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
The business case for regulated AI turns on the cost of producing an outcome that the quality system can accept.
In October, FDA reorganized rare disease development around a fit-for-purpose framework and a new pathway for individualized gene editing. Regulators in Europe and the UK set out long-term plans for clinical trials, AI, and moving away from animal testing.
Clinical, manufacturing, safety, and commercial teams all lean on shared data. They need to agree on who publishes each data product, who can use it, and what evidence goes with it.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
2
Improving Oral Peptide Delivery Through Structural Modifications
3
Using OEE Monitoring to Justify Expenditure on Aging Production Lines
4
Drapeau’s AI Deep Dive: The Price of Acceptance in Regulated AI
5